Home » Topics » BioWorld Science

BioWorld Science
RSS

Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia

Aug. 6, 2021

Enrollment starts in phase I study of ZYIL-1

Aug. 6, 2021

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Aug. 6, 2021

Dosing begins in phase II portion of phase I/II trial of AKS-452

Aug. 6, 2021

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Aug. 6, 2021

MYMD-1 shows the ability to suppress cytokine storm in human cells

Aug. 6, 2021

Clene provides topline data from REPAIR-PD and REPAIR-MS studies

Aug. 6, 2021

First patient dosed in IMP-MEL study of PORT-2 for the treatment of melanoma and NSCLC

Aug. 6, 2021

INPP5D inhibition reduces amyloid pathology in Alzheimer's disease model

Aug. 6, 2021

Exicure provides updated interim data from phase Ib/II study of cavrotolimod

Aug. 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...